Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 7
1982 2
1983 7
1984 7
1985 6
1986 8
1987 19
1988 7
1989 16
1990 12
1991 21
1992 17
1993 11
1994 15
1995 20
1996 7
1997 13
1998 12
1999 10
2000 18
2001 12
2002 17
2003 16
2004 11
2005 14
2006 14
2007 9
2008 7
2009 11
2010 7
2011 8
2012 9
2013 9
2014 3
2015 9
2016 3
2017 5
2018 2
2019 2
2020 2
2021 7
2022 4
2023 2
2024 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

403 results

Results by year

Filters applied: . Clear all
Page 1
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
Wardlaw JM, Woodhouse LJ, Mhlanga II, Oatey K, Heye AK, Bamford J, Cvoro V, Doubal FN, England T, Hassan A, Montgomery A, O'Brien JT, Roffe C, Sprigg N, Werring DJ, Bath PM; Lacunar Intervention Trial-2 (LACI-2) Investigator Group. Wardlaw JM, et al. JAMA Neurol. 2023 Jul 1;80(7):682-692. doi: 10.1001/jamaneurol.2023.1526. JAMA Neurol. 2023. PMID: 37222252 Free PMC article. Clinical Trial.
OBJECTIVE: To test the feasibility, drug tolerability, safety, and effects of 1-year isosorbide mononitrate (ISMN) and cilostazol treatment on vascular, functional, and cognitive outcomes in patients with lacunar stroke. ...Compared with those participants not recei …
OBJECTIVE: To test the feasibility, drug tolerability, safety, and effects of 1-year isosorbide mononitrate (ISMN) and cilosta …
Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial.
Blair GW, Janssen E, Stringer MS, Thrippleton MJ, Chappell F, Shi Y, Hamilton I, Flaherty K, Appleton JP, Doubal FN, Bath PM, Wardlaw JM. Blair GW, et al. Stroke. 2022 Jan;53(1):29-33. doi: 10.1161/STROKEAHA.121.034866. Epub 2021 Dec 1. Stroke. 2022. PMID: 34847709 Free PMC article. Clinical Trial.
BACKGROUND AND PURPOSE: Cerebral small vessel disease-a major cause of stroke and dementia-is associated with cerebrovascular dysfunction. We investigated whether short-term isosorbide mononitrate (ISMN) and cilostazol, alone or in combination, improved magnetic res …
BACKGROUND AND PURPOSE: Cerebral small vessel disease-a major cause of stroke and dementia-is associated with cerebrovascular dysfunction. W …
Prevention of variceal rebleeding.
Bosch J, García-Pagán JC. Bosch J, et al. Lancet. 2003 Mar 15;361(9361):952-4. doi: 10.1016/S0140-6736(03)12778-X. Lancet. 2003. PMID: 12648985 Review.
Drug approaches are based on non-selective beta blocker with or without isosorbide-5-mononitrate (ISMN). STARTING POINT: David Patch and colleagues (Gastroenterology 2002; 123: 1013-19) randomised 102 patients surviving a variceal bleeding to EBL or drug ther …
Drug approaches are based on non-selective beta blocker with or without isosorbide-5-mononitrate (ISMN). STARTING POINT …
Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease.
Neuhaus R, Johnen R, Vydra L, Solbach C. Neuhaus R, et al. Pharmatherapeutica. 1986;4(8):486-95. Pharmatherapeutica. 1986. PMID: 3086899 Clinical Trial.
There was no significant difference between drugs as regards ST segment reduction but a slight difference in favour of isosorbide 5-mononitrate (p less than 0.05) in terms of maximal exercise level and work capacity. Both drugs resulted in very small reductio …
There was no significant difference between drugs as regards ST segment reduction but a slight difference in favour of isosorbide …
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850).
Bath PM, Mhlanga I, Woodhouse LJ, Doubal F, Oatey K, Montgomery AA, Wardlaw JM; LACI-2 Trial Investigators. Bath PM, et al. Stroke Vasc Neurol. 2023 Apr;8(2):134-143. doi: 10.1136/svn-2022-001816. Epub 2022 Sep 2. Stroke Vasc Neurol. 2023. PMID: 36219567 Free PMC article. Clinical Trial.
METHODS: The LACunar Intervention Trial-2 is an investigator-initiated prospective randomised open-label blinded-endpoint phase II feasibility study assessing cilostazol and isosorbide mononitrate for preventing SVD progression. We aimed to recruit 400 patients with …
METHODS: The LACunar Intervention Trial-2 is an investigator-initiated prospective randomised open-label blinded-endpoint phase II feasibili …
Intravaginal administration of isosorbide mononitrate for cervical ripening in prolonged pregnancy: a randomised clinical trial.
Mirteimouri M, Pourali L, Najaf Najafi M, Ghaffarian Omid M. Mirteimouri M, et al. J Obstet Gynaecol. 2020 Aug;40(6):792-796. doi: 10.1080/01443615.2019.1669546. Epub 2019 Dec 18. J Obstet Gynaecol. 2020. PMID: 31852287 Clinical Trial.
This study was performed to evaluate the efficacy of intravaginal isosorbide mononitrate (IMN) for cervical ripening in prolonged pregnancies. 122 pregnant women were recruited. ...According to results of the current study; using isosorbide mononitrate …
This study was performed to evaluate the efficacy of intravaginal isosorbide mononitrate (IMN) for cervical ripening in prolon …
Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial.
Collingham JP, Fuh KC, Caughey AB, Pullen KM, Lyell DJ, El-Sayed YY. Collingham JP, et al. Obstet Gynecol. 2010 Jul;116(1):121-126. doi: 10.1097/AOG.0b013e3181e408f2. Obstet Gynecol. 2010. PMID: 20567177 Clinical Trial.
OBJECTIVE: To estimate whether vaginal isosorbide mononitrate, added to oral misoprostol for cervical ripening and labor induction, shortens time to vaginal delivery. ...Seventy-eight women received misoprostol, and 78 received misoprostol with isosorbide …
OBJECTIVE: To estimate whether vaginal isosorbide mononitrate, added to oral misoprostol for cervical ripening and labor induc …
Pharmacokinetics and Safety with Bioequivalence of Isosorbide Mononitrate Sustained-Release Tablets in Chinese Healthy Volunteers: Bioequivalence Study.
Wu B, Wang W, Zhang Q, Yu G, Lin J, Zhang T, Ye L, Wang K, Zhang W, Wu X. Wu B, et al. Drug Des Devel Ther. 2025 Jul 14;19:6025-6035. doi: 10.2147/DDDT.S508202. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40687901 Free PMC article. Clinical Trial.
PURPOSE: Isosorbide mononitrate was recommended for controlling anginal symptoms in patients with cardiovascular disease. ...Subjects received single dose 40-mg/tablet isosorbide mononitrate in each period with a 5-day washout. Serial blood samples wer …
PURPOSE: Isosorbide mononitrate was recommended for controlling anginal symptoms in patients with cardiovascular disease. ...S …
Effects of Nicorandil, Isosorbide Mononitrate, or Diltiazem on Radial Artery Grafts After CABG: The Randomized ASRAB-Pilot Trial.
Zhu Y, Zhang W, Qin K, Liu Y, Yao H, Wang Z, Ye X, Zhou M, Li H, Qiu J, Xu H, Sun Y, Gaudino M, Zhao Q. Zhu Y, et al. Circ Cardiovasc Interv. 2025 Apr;18(4):e014542. doi: 10.1161/CIRCINTERVENTIONS.124.014542. Epub 2025 Mar 24. Circ Cardiovasc Interv. 2025. PMID: 40123490 Clinical Trial.
The RA graft failure rates were slightly higher with nicorandil versus isosorbide mononitrate (19.4% versus 18.2%; difference, 1.2% [95% CI, -13.3% to 15.2%]). ...CONCLUSIONS: In this pilot trial, treatment with nicorandil or isosorbide mononitrate was …
The RA graft failure rates were slightly higher with nicorandil versus isosorbide mononitrate (19.4% versus 18.2%; difference, …
Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial.
Jamal SA, Cummings SR, Hawker GA. Jamal SA, et al. J Bone Miner Res. 2004 Sep;19(9):1512-7. doi: 10.1359/JBMR.040716. Epub 2004 Jul 26. J Bone Miner Res. 2004. PMID: 15312252 Free article. Clinical Trial.
MATERIALS AND METHODS: We randomly assigned 144 healthy postmenopausal women with a hip BMD T score between 0 and -2.5 to 5 or 20 mg/day of isosorbide mononitrate (ISMO) or placebo for 12 weeks. We measured urine N-telopeptide (NTx), a marker of bone resorption, and …
MATERIALS AND METHODS: We randomly assigned 144 healthy postmenopausal women with a hip BMD T score between 0 and -2.5 to 5 or 20 mg/day of …
403 results